EULAR 2018

Biosimilars featured prominently in research presented at the European League Against Rheumatism's Annual European Congress of Rheumatology. Here are 9 key takeaways from the meeting. 
Rituximab has previously been shown to be effective at doses of 1000 mg in treating patients with rheumatoid arthritis (RA) who had previously received other biologic agents. Research presented at the European League Against Rheumatism's Annual European Congress of Rheumatology demonstrates that using lower doses of biosimilar rituximab—which may provide a substantial cost savings—is also effective.
At the European League Against Rheumatism Annual European Congress of Rheumatology, researchers presented findings on 3 studies in which patients switched to a biosimilar etanercept molecule from the reference Enbrel.
During the European League Against Rheumatism’s Annual European Congress of Rheumatology, held from June 13-16 in Amsterdam, Netherlands, researchers presented findings on adalimumab biosimilars, referencing Humira.
 
At the European League Against Rheumatism (EULAR)'s Annual European Congress of Rheumatology, held from June 13-16 in Amsterdam, Netherlands, researchers reported on Biocad’s Russian-authorized biosimilar infliximab, BCD-055, and on switches to the widely approved infliximab biosimilar CT-P13 (Inflectra, Remsima).
At the European League Against Rheumatism’s Annual European Congress of Rheumatology, held from June 13-16 in Amsterdam, Netherlands, the patient experience with switching to biosimilars from their reference products is a key topic among stakeholders.
During the European League Against Rheumatism’s Annual European Congress of Rheumatology, researchers published findings on the economic impacts of nonmedical switching; while 1 study found that switching to biosimilar infliximab brought down costs without sacrificing efficacy or safety, but another raised concerns about increases in overall healthcare utilization.
At the 2018 European League Against Rheumatism’s (EULAR) Annual Congress of Rheumatology, attendees and exhibitors had the opportunity to learn from several internationally recognized speakers, who provided nearly 800 oral presentations over more than 150 sessions. Additionally, the conference offered the chance to view more than 2,300 posters.
 
From June 13-16, 2018, attendees at the EULAR Annual Congress of Rheumatology were able to network with some of the best and brightest from the industry. Those who were not in attendance, however, can rely on The Center for Biosimilars for the most comprehensive coverage of the conference, including breaking news articles and video interviews featuring key opinion leaders.

Click here to view Biosimilars CME Activities

Click here to view Biosimilars PTCE Activities


Health economics experts. Managed care professionals. Key clinical specialists. This is where the worlds of clinical, regulatory, and economical outcomes for specialized pharmaceutical biotechnology meet: The Center for Biosimilars is your online resource for emerging technologies, with a focus on improving critical thinking in the field to impact patient outcomes. We’ll discuss the current landscape for advanced health care management—reviewing emerging treatment paradigms, approaches, and considerations—all by authoritative industry voices.

Intellisphere, LLC
2 Clarke Drive
Suite 100
Cranbury, NJ 08512
P: 609-716-7777
F: 609-716-4747
Copyright © 2006-2018 Intellisphere, LLC. All Rights Reserved.